Adequate supply level has been restored in all EU Member States and pegylated doxorubicin hydrochloride can now be used again without restrictions

The European Medicines Agency has announced that it has updated its recommendations on the use of Caelyx which were issued in the last two years. These recommendations followed a shortage of the medicine due to shortcomings in quality assurance identified at the manufacturing site, Ben Venue Laboratories. The Agency’s Committee for Medicinal Products for Human Use now considers that adequate supply levels have been restored in all EU Member States and that Caelyx can now be used again without restrictions as per its licensed indications. There is no longer a need to prioritise existing patients and new patients for whom no alternative treatment is available. Read more here.